Cephalon Drops Patent Suit Vs. Sandoz Over Provigil
According to Cephalon, Sandoz has decided not to challenge Cephalon's patent position on Provigil, a treatment for excessive day-time sleepiness. Instead, Sandoz will wait until 2014 to seek to put out a generic version of the drug, when a patent on one of Provigil's key ingredients is set to expire.
Instead, Sandoz plans to convert its abbreviated new drug...
To view the full article, register now.